U.S. sales of EYLEA HD and EYLEA, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...

Regeneron Pharmaceuticals, Inc. (REGN) reported second-quarter 2025 adjusted earnings per share (EPS) of $12.89, which ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

Regeneron Pharmaceuticals (NASDAQ:REGN) on Friday topped Street forecasts with its Q2 financials, thanks mainly to U.S. sales ...

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron's Lynozyfic ...

(REGN) on Friday reported second-quarter earnings of $1.39 billion. The Tarrytown, New York-based company said it ...

Net Margin: Regeneron Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 26.7%, the company demonstrates strong profitability and effective cost management.